Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Kendall Diebold, Todd Mudd, Jay Jarodiya, Katherine Parks, Maris Hardee, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Manuel Espinoza-Gutarra, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2024) 144 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2024-204120

Published: 2024

Journal Articles

Effect of Lumbar Puncture Timing on Neurotoxicity with Blinatumomab Therapy in a Real-World Cohort of Acute Lymphoblastic Leukemia (ALL)

Sravanti Rangaraju, Kendall Diebold, Pankit Vachhani, Omer Jamy, Kimo Bachiashvili, Ravi Bhatia, Razan Mohty, Manuel Espinoza-Gutarra, Joshua Oliver, Barry Diamond, Kaitlin Moulton, Zaid Al-Kadhimi

Blood (2024) 144 (Supplement 1): 2808.

https://doi.org/10.1182/blood-2024-211985

Published: 2024

Journal Articles

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2023-189853

Published: 2023

Journal Articles

Real-World Evidence of Treatment-Free Remission in Chronic Myeloid Leukemia at an Academic Center in the Deep South

Greg Bascug, Garrett Bourne, Kendall Diebold, Joshua Knapp, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 7425.

https://doi.org/10.1182/blood-2023-184757

Published: 2023

Journal Articles

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Kendall Diebold, Sarah Worth, Kimo Bachiashvili, Pankit Vachhani, Sravanti Rangaraju, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5910.

https://doi.org/10.1182/blood-2023-185198

Published: 2023

Journal Articles

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Justin Layer, Sravanti Rangaraju, Santhosh Pasupuleti, Larry D. Cripe, Hamid Sayar, Katie J Sargent, Jill Weisenbach, Huda S. Salman, G. David Roodman, Linsey Mayo, Reuben Kapur, Utpal P Dave', H. Scott Boswell

Blood (2022) 140 (Supplement 1): 11546–11547.

https://doi.org/10.1182/blood-2022-156329

Published: 2022

Journal Articles

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Omer H Jamy, Kendall Diebold, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Kelly N. Godby, Donna Salzman, Ravi Bhatia

Blood (2022) 140 (Supplement 1): 8959–8960.

https://doi.org/10.1182/blood-2022-160346

Published: 2022

Journal Articles

Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Omer Hassan Jamy, Sarah Worth, Sravanti Rangaraju, Kimo Bachiashvili, Pankit Vachhani, Ravi Bhatia

Blood (2021) 138 (Supplement 1): 2322.

https://doi.org/10.1182/blood-2021-149778

Published: 2021

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease

Alyson Swimm, Cynthia R. Giver, Zachariah DeFilipp, Sravanti Rangaraju, Akshay Sharma, Alina Ulezko Antonova, Robert Sonowal, Christopher Capaldo, Domonica Powell, Muna Qayed, Daniel Kalman, Edmund K. Waller

Blood (2018) 132 (23): 2506–2519.

https://doi.org/10.1182/blood-2018-03-838193

Published: 2018

Includes: Supplemental data

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

Lateral Gene Transfer Contributing to Leukemogenesis

Joo Hyun Lee, BS, Cynthia R. Giver, PhD, Sravanti Rangaraju, MD MBBS, Edmund K Waller, MD PhD

Blood (2015) 126 (23): 1235.

https://doi.org/10.1182/blood.V126.23.1235.1235

Published: 2015

Journal Articles

Incidence of Unprovoked Venous Thromboembolic Events in Patients with Chronic Lymphocytic Leukemia (CLL)

Lauren Angela Katkish, MD, Sravanti Rangaraju, MD MBBS, Thomas S Rector, PharmD, PhD, Gerhard J Johnson, MD, Mark A Klein, MD, Pankaj Gupta, MD

Blood (2015) 126 (23): 1110.

https://doi.org/10.1182/blood.V126.23.1110.1110

Published: 2015

Journal Articles

Administration of a Tryptophan Metabolite, Indole-3-Carboxaldehyde, Reduces Graft Versus Host Disease Morbidity and Mortality and Enhances Gastrointestinal Barrier Function in a Murine Model of Allogeneic Bone Marrow Transplantation

Edmund K. Waller, MD PhD, Cynthia R. Giver, PhD, Sravanti Rangaraju, MBBS, Alyson Swimm, BS, Akshay Sharma, MD, Muna Qayed, MD, Zachariah Defilipp, MD, Daniel Kalman, PhD

Blood (2014) 124 (21): 2420.

https://doi.org/10.1182/blood.V124.21.2420.2420

Published: 2014

Journal Articles

Blocking VIP Signaling Abrogates Upregulation Of PD1 and Increases Proliferation Of Allo-Reactive T-Cells In a Mixed Lymphocyte Reaction

Emily R Summerbell, Cynthia R. Giver, PhD, Sravanti Rangaraju, MBBS, Katarzyna Anna Darlak, Graduate, Edmund K. Waller, MD, PhD

Blood (2013) 122 (21): 1041.

https://doi.org/10.1182/blood.V122.21.1041.1041

Published: 2013

Journal Articles

Pharmacological Inhibition Of Semi-Direct Alloantigen Presentation and The Generation Of Cross-Dressed Antigen Presenting Cells: A Novel approach To Limit Graft Versus Host Disease Following Allogeneic Hematopoetic Stem Cell Transplantation

Sravanti Rangaraju, MBBS, Junghwa Choi, Cynthia R. Giver, PhD, Edmund K. Waller, MD, PhD

Blood (2013) 122 (21): 294.

https://doi.org/10.1182/blood.V122.21.294.294

Published: 2013

NARROW

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Effect of Lumbar Puncture Timing on Neurotoxicity with Blinatumomab Therapy in a Real-World Cohort of Acute Lymphoblastic Leukemia (ALL)

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Real-World Evidence of Treatment-Free Remission in Chronic Myeloid Leukemia at an Academic Center in the Deep South

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Lateral Gene Transfer Contributing to Leukemogenesis

Incidence of Unprovoked Venous Thromboembolic Events in Patients with Chronic Lymphocytic Leukemia (CLL)

Administration of a Tryptophan Metabolite, Indole-3-Carboxaldehyde, Reduces Graft Versus Host Disease Morbidity and Mortality and Enhances Gastrointestinal Barrier Function in a Murine Model of Allogeneic Bone Marrow Transplantation

Blocking VIP Signaling Abrogates Upregulation Of PD1 and Increases Proliferation Of Allo-Reactive T-Cells In a Mixed Lymphocyte Reaction

Pharmacological Inhibition Of Semi-Direct Alloantigen Presentation and The Generation Of Cross-Dressed Antigen Presenting Cells: A Novel approach To Limit Graft Versus Host Disease Following Allogeneic Hematopoetic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only